US4775624A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vectors and compounds for expression of human protein C
Assignee: Eli Lilly and Co
•
Filing: 1985-02-08
•
Granted: 1988-10-04
•
Expires: 2005-02-08
Abstract
Abstract The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
Inventors
- 👤 Nils U. Bang
- 👤 Robert J. Beckmann
- 👤 S. Richard Jaskunas
- 👤 Mei-Huei T. Lai
- 👤 Shelia P. Little
- 👤 George L. Long
- 👤 Robert F. Santerre
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 22:26
CPC Classifications
C; C12; C12N; C12N15/00; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6464; A; A61; A61P; A61P7/00; A61P7/02; C12Y; C12Y304/00; C12Y304/21; C12Y304/21069; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/832; Y10S435/848; Y10S435/849; Y10S435/886
Claims Analysis
Total Claims: 85
Claim 1
Independent Claim
684 words
A constructed DNA compound that comprises double-stranded deoxyribonucleic acid that encodes a polypeptide with human protein C activity, wherein the coding strand is: __________________________________________________________________________
.sup.5'-R.spsp.1 N.sup.--R M--GCC
AAC TCC TTC CTG GAG GAG CTC CGT CAC AGC
AGC CTG GAG CGG GAG TGC ATA GAG GAG ATC TGT GAC TTC GAG
GAG GCC AAG GAA ATT TTC CAA AAT GTG GAT GAC ACA CTG GCC
TTC TGG TCC AAG CAC GTC GAC GGT GAC CAG TGC TTG GTC TTG
CCC TTG GAG CAC CCG TGC GCC AGC CTG TGC TGC GGG CAC GGC
ACG TGC ATC GAC GGC ATC GGC AGC TTC AGC TGC GAC TGC CGC
AGC GGC TGG GAG GGC CGC TTC TGC CAG CGC GAG GTG AGC TTC
CTC AAT TGC TCG CTG GAC AAC GGC GGC TGC ACG CAT TAC TGC
CTA GAG GAG GTG GGC TGG CGG CGC TGT AGC TGT GCG CCT GGC
TAC AAG CTG GGG GAC GAC CTC CTG CAG TGT CAC CCC GCA GTG
AAG TTC CCT TGT GGG AGG CCC TGG AAG CGG ATG GAG AAG AAG
CGC AGT CAC CTG AAA CGA GAC ACA GAA GAC CAA GAA GAC CAA
GTA GAT CCG CGG CTC ATT GAT GGG AAG ATG ACC AGG CGG GGA
GAC AGC CCC TGG CAG GTG GTC CTG CTG GAC TCA AAG AAG AAG
CTG GCC TGC GGG GCA GTG CTC ATC CAC CCC TCC TGG GTG CTG
ACA GCG GCC CAC TGC ATG GAT GAG TCC AAG AAG CTC CTT GTC
AGG CTT GGA GAG TAT GAC CTG CGG CGC TGG GAG AAG TGG GAG
CTG GAC CTG GAC ATC AAG GAG GTC TTC GTC CAC CCC AAC TAC
AGC AAG AGC ACC ACC GAC AAT GAC ATC GCA CTG CTG CAC CTG
GCC CAG CCC GCC ACC CTC TCG CAG ACC ATA GTG CCC ATC TGC
CTC CCG GAC AGC GGC CTT GCA GAG CGC GAG CTC AAT CAG GCC
GGC CAG GAG ACC CTC GTG ACG GGC TGG GGC TAC CAC AGC AGC
CGA GAG AAG GAG GCC AAG AGA AAC CGC ACC TTC GTC CTC AAC
TTC ATC AAG ATT CCC GTG GTC CCG CAC AAT GAG TGC AGC GAG
GTC ATG AGC AAC ATG GTG TCT GAG AAC ATG CTG TGT GCG GGC
ATC CTC GGG GAC CGG CAG GAT GCC TGC GAG GGC GAC AGT GGG
GGG CCC ATG GTC GCC TCC TTC CAC GGC ACC TGG TTC CTG GTG
GGC CTG GTG AGC TGG GGT GAG GGC TGT GGG CTC CTT CAC AAC
TAC GGC GTT TAC ACC AAA GTC AGC CGC TAC CTC GAC TGG ATC
CAT GGG CAC ATC AGA GAC AAG GAA GCC CCC CAG AAG AGC TGG
GCA CCT TAG--3'
__________________________________________________________________________ wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytidyl, T is thymidyl, R is 5'-GCC CAC CAG GTG CTG CGG ATC CGC AAA CGT-3' or 5'-CAC CAG GTG CTG CGG ATC CGC AAA CGT-3' R 1 is __________________________________________________________________________
5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT--3'
or 5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT
GCC--3'
__________________________________________________________________________ M is 0 or 1, and N is 0 or 1, provided that when M is 0, N must necessarily also be 0 and that when R is 5'-GCC CAC CAG GTG CTG CGG ATC CGC AAA CGT-3', R 1 must necessarily be __________________________________________________________________________
5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT--3';
__________________________________________________________________________ and that when R is 5'-CAC CAG GTG CTG CGG ATC CGC AAA CGT-3', R 1 must necessarily be __________________________________________________________________________
5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT
GCC--3'.
__________________________________________________________________________
Claim 2
Dependent Claim
684 words
A constructed DNA compound that comprises double-stranded deoxyribonucleic acid that encodes a polypeptide with human protein C activity, wherein the coding strand is: __________________________________________________________________________
.sup.5'-R.spsp.1 N.sup.--R M--GCC
AAC TCC TTC CTG GAG GAG CTC CGT CAC AGC
AGC CTG GAG CGG GAG TGC ATA GAG GAG ATC TGT GAC TTC GAG
GAG GCC AAG GAA ATT TTC CAA AAT GTG GAT GAC ACA CTG GCC
TTC TGG TCC AAG CAC GTC GAC GGT GAC CAG TGC TTG GTC TTG
CCC TTG GAG CAC CCG TGC GCC AGC CTG TGC TGC GGG CAC GGC
ACG TGC ATC GAC GGC ATC GGC AGC TTC AGC TGC GAC TGC CGC
AGC GGC TGG GAG GGC CGC TTC TGC CAG CGC GAG GTG AGC TTC
CTC AAT TGC TCG CTG GAC AAC GGC GGC TGC ACG CAT TAC TGC
CTA GAG GAG GTG GGC TGG CGG CGC TGT AGC TGT GCG CCT GGC
TAC AAG CTG GGG GAC GAC CTC CTG CAG TGT CAC CCC GCA GTG
AAG TTC CCT TGT GGG AGG CCC TGG AAG CGG ATG GAG AAG AAG
CGC AGT CAC CTG AAA CGA GAC ACA GAA GAC CAA GAA GAC CAA
GTA GAT CCG CGG CTC ATT GAT GGG AAG ATG ACC AGG CGG GGA
GAC AGC CCC TGG CAG GTG GTC CTG CTG GAC TCA AAG AAG AAG
CTG GCC TGC GGG GCA GTG CTC ATC CAC CCC TCC TGG GTG CTG
ACA GCG GCC CAC TGC ATG GAT GAG TCC AAG AAG CTC CTT GTC
AGG CTT GGA GAG TAT GAC CTG CGG CGC TGG GAG AAG TGG GAG
CTG GAC CTG GAC ATC AAG GAG GTC TTC GTC CAC CCC AAC TAC
AGC AAG AGC ACC ACC GAC AAT GAC ATC GCA CTG CTG CAC CTG
GCC CAG CCC GCC ACC CTC TCG CAG ACC ATA GTG CCC ATC TGC
CTC CCG GAC AGC GGC CTT GCA GAG CGC GAG CTC AAT CAG GCC
GGC CAG GAG ACC CTC GTG ACG GGC TGG GGC TAC CAC AGC AGC
CGA GAG AAG GAG GCC AAG AGA AAC CGC ACC TTC GTC CTC AAC
TTC ATC AAG ATT CCC GTG GTC CCG CAC AAT GAG TGC AGC GAG
GTC ATG AGC AAC ATG GTG TCT GAG AAC ATG CTG TGT GCG GGC
ATC CTC GGG GAC CGG CAG GAT GCC TGC GAG GGC GAC AGT GGG
GGG CCC ATG GTC GCC TCC TTC CAC GGC ACC TGG TTC CTG GTG
GGC CTG GTG AGC TGG GGT GAG GGC TGT GGG CTC CTT CAC AAC
TAC GGC GTT TAC ACC AAA GTC AGC CGC TAC CTC GAC TGG ATC
CAT GGG CAC ATC AGA GAC AAG GAA GCC CCC CAG AAG AGC TGG
GCA CCT TAG--3'
__________________________________________________________________________ wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytidyl, T is thymidyl, R is 5'-GCC CAC CAG GTG CTG CGG ATC CGC AAA CGT-3' or 5'-CAC CAG GTG CTG CGG ATC CGC AAA CGT-3' R 1 is __________________________________________________________________________
5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT--3'
or 5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT
GCC--3'
__________________________________________________________________________ M is 0 or 1, and N is 0 or 1, provided that when M is 0, N must necessarily also be 0 and that when R is 5'-GCC CAC CAG GTG CTG CGG ATC CGC AAA CGT-3', R 1 must necessarily be __________________________________________________________________________
5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT--3';
__________________________________________________________________________ and that when R is 5'-CAC CAG GTG CTG CGG ATC CGC AAA CGT-3', R 1 must necessarily be __________________________________________________________________________
5'-ATG
TGG CAG CTC ACA AGC CTC CTG CTG TTC
GTG
GCC ACC TGG GGA ATT TCC GGC ACA CCA GCT
CCT
CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT
GCC--3'.
__________________________________________________________________________
Claim 3
Dependent Claim
8 words
A plasmid comprising the DNA of claim 1.
Claim 4
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pHC7.
Claim 5
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pSV2-HCP8.
Claim 6
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pMSV-HPC.
Claim 7
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pL133.
Claim 8
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pL132.
Claim 9
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pL151.
Claim 10
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pL141.
Claim 11
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pL142.
Claim 12
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pMMTΔBPV-HPC.
Claim 13
Dependent Claim
116 words
A method of producing a polypeptide with human protein C activity in a eukaryotic host cell, said method comprising: A. transforming said eukaryotic host cell with a recombinant DNA vector, said vector comprising: (i) a DNA sequence that provides for autonomous replication or chromosomal integration of said vector in said host cell; (ii) a promoter and translational activating sequence functional in said host cell; and (iii) a DNA compound of claim 1 positioned in transcriptional and translational reading phase with said promoter and translational activating sequence, provided that when N=1, said translational activating sequence does not encode a translational start codon; B. culturing said host cell transformed in step A under conditions suitable for gene expression.
Claim 14
Dependent Claim
39 words
The method of claim 12, wherein said host cell is selected from the group consisting of cells of HepG-2, Aedes aegypti, CV-1, LLC-MK 2 , 3T3, CHO-K1, CHO-K1 (dhfr - ), Anthraea eucalypti, HeLa, RPMI8226, H4IIEC3, C127I, and HS-Sultan.
Claim 15
Dependent Claim
16 words
The method of claim 13, wherein said host cell is selected from the cell line HepG-2.
Claim 16
Dependent Claim
17 words
The method of claim 13, wherein said host cell is selected from the cell line Aedes aegypti.
Claim 17
Dependent Claim
16 words
The method of claim 13, wherein said host cell is selected from the cell line C127I.
Claim 18
Dependent Claim
18 words
The method of claim 13, wherein said host cell is selected from the cell line LLC-MK 2 .
Claim 19
Dependent Claim
16 words
The method of claim 13, wherein said host cell is selected from the cell line 3T3.
Claim 20
Dependent Claim
16 words
The method of claim 13, wherein said host cell is selected from the cell line H4IIEC3.
Claim 21
Dependent Claim
15 words
The method of claim 14, wherein the host cell cultured in step B is HepG-2/pL133.
Claim 22
Dependent Claim
15 words
The method of claim 14, wherein the host cell cultured in step B is HepG-2/pSV2-HPC8.
Claim 23
Dependent Claim
15 words
The method of claim 18, wherein the host cell cultured in step B is 3T3/pL142.
Claim 24
Dependent Claim
15 words
The method of claim 16, wherein the host cell cultured in step B is C127I/pSV2-HPC8.
Claim 25
Dependent Claim
22 words
The method of claim 12, wherein said recombinant DNA vector further comprises a selectable marker that functions in said eukaryotic host cell.
Claim 26
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is HepG-2/pL132.
Claim 27
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is HepG-2/pL151.
Claim 28
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is HepG-2/pL141.
Claim 29
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is HepG-2/pMSV-HPC.
Claim 30
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is RPMI8226/pL151.
Claim 31
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is RPMI8226/pL132.
Claim 32
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is RPMI8226/pMSV-HPC.
Claim 33
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is RPMI8226/pL141.
Claim 34
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is CV-1/pL132.
Claim 35
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is CV-1/pL151.
Claim 36
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is CV-1/pL141.
Claim 37
Dependent Claim
17 words
The method of claim 24, wherein the host cell cultured in step B is LLC-MK 2 /pL132.
Claim 38
Dependent Claim
17 words
The method of claim 24, wherein the host cell cultured in step B is CHO-K1(dhfr - )/pL141.
Claim 39
Dependent Claim
17 words
The method of claim 24, wherein the host cell cultured in step B is LLC-MK 2 /pL141.
Claim 40
Dependent Claim
17 words
The method of claim 24, wherein the host cell cultured in step B is LLC-MK 2 /pL151.
Claim 41
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is 3T3/pL132.
Claim 42
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is CHO-K1/pL151.
Claim 43
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is 3T3/pMMTΔBPV-HPC.
Claim 44
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is CHO-K1/pL141.
Claim 45
Dependent Claim
17 words
The method of claim 24, wherein the host cell cultured in step B is CHO-K1(dhfr - )/pL151.
Claim 46
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is HeLa/pL132.
Claim 47
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is CHO-K1/pMSV-HPC.
Claim 48
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is H4IIEC3/pL132.
Claim 49
Dependent Claim
17 words
The method of claim 24, wherein the host cell cultured in step B is CHO-K1(dhfr - )/pMSV-HPC.
Claim 50
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is H4IIEC3/pMMTΔBPV-HPC.
Claim 51
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is H4IIEC3/pL141.
Claim 52
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is C127I/pL151.
Claim 53
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is C127I/pMMTΔBPV-HPC.
Claim 54
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is C127I/pL141.
Claim 55
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is HS-Sultan/pL132.
Claim 56
Dependent Claim
15 words
The method of claim 24, wherein the host cell cultured in step B is HS-Sultan/pL141.
Claim 57
Dependent Claim
13 words
The host cell used in the method of claim 20 which is HepG-2/pL133.
Claim 58
Dependent Claim
13 words
The host cell used in the method of claim 23 which is C127I/pSV2-HPC8.
Claim 59
Dependent Claim
13 words
The host cell used in the method of claim 25 which is HepG-2/pL132.
Claim 60
Dependent Claim
13 words
The host cell used in the method of claim 26 which is HepG-2/pL151.
Claim 61
Dependent Claim
13 words
The host cell used in the method of claim 27 which is HepG-2/pL141.
Claim 62
Dependent Claim
13 words
The host cell used in the method of claim 32 which is RPMI8226/pL141.
Claim 63
Dependent Claim
13 words
The host cell used in the method of claim 35 which is CV-1/pL141.
Claim 64
Dependent Claim
15 words
The host cell used in the method of claim 36 which is LLC-MK 2 /pL132.
Claim 65
Dependent Claim
13 words
The host cell used in the method of claim 41 which is CHO-K1/pL151.
Claim 66
Dependent Claim
13 words
The host cell used in the method of claim 43 which is CHO-K1/pL141.
Claim 67
Dependent Claim
15 words
The host cell used in the method of claim 44 which is CHO-K1(dhfr - )/pL151.
Claim 68
Dependent Claim
13 words
The host cell used in the method of claim 52 which is C127I/pMMTΔBPV-HPC.
Claim 69
Dependent Claim
15 words
The double-stranded deoxyribonucleic acid of claim 1, wherein N is 0 and M is 1.
Claim 70
Dependent Claim
105 words
A method of producing human protein C activity in a prokaryotic host cell, said method comprising: A. transforming said prokaryotic host cell with a recombinant DNA vector, said vector comprising: (i) a DNA sequence that provides for autonomous replication or chromosomal integration of said vector in said host cell; (ii) a promoter and translational activating sequence functional in said host cell; (iii) a DNA compound of claim 1, wherein N=0 and M=0 or 1, positioned in transcriptional and translational reading phase with said promoter and translational activating sequence; and (iv) a selectable marker; B. culturing said prokaryotic host cell under conditions suitable for gene expression.
Claim 71
Dependent Claim
22 words
The method of claim 69, wherein said prokaryotic host cell is selected from the group consisting of Bacillus, Streptomyces, and E. coli.
Claim 72
Dependent Claim
13 words
The method of claim 70, wherein said host cell is E. coli K12.
Claim 73
Dependent Claim
14 words
The method of claim 71, wherein said host cell is E. coli K12 RV308.
Claim 74
Dependent Claim
14 words
The method of claim 71, wherein said host cell is E. coli K12 MM294.
Claim 75
Dependent Claim
14 words
The method of claim 71, wherein said host cell is E. coli K12 RR1.
Claim 76
Dependent Claim
14 words
The method of claim 71, wherein said host cell is E. coli K12 RR1ΔM15.
Claim 77
Dependent Claim
16 words
A plasmid selected from the group consisting of pUC19HC, pCZ118, pCZ10, pCZ11, pCZ451, pCZ459, and pCZ455.
Claim 78
Dependent Claim
16 words
A plasmid selected from the group consisting of pUC19HC, pCZ118, pCZ10, pCZ11, pCZ451, pCZ459, and pCZ455.
Claim 79
Dependent Claim
9 words
The plasmid of claim 2 that is plasmid pCZ460.
Claim 80
Dependent Claim
19 words
The host cell cultured in step B of the method of claim 72 that is E. coli K12 RV308/pCZ460.
Claim 81
Dependent Claim
19 words
The host cell cultured in step B of the method of claim 73 that is E. coli K12 MM294/pCZ460.
Claim 82
Dependent Claim
20 words
A method of claim 12, wherein said host cell is a CHO-K1 host cell, including the dhfr - derivatives thereof.
Claim 83
Dependent Claim
94 words
A constructed, recombinant DNA sequence that comprises the coding sequence for the active light chain of human protein C, said active light chain having the amino acid residue sequence: ##STR15## wherein ALA is Alanine, ARG is Arginine, ASN is Asparagine, ASP is Aspartic Acid, CYS is Cysteine, GLN is Glutamine, GLU is Glutamic Acid, GLY is Glycine, HIS is Histidine, ILE is Isoleucine, LEU is Leucine, LYS is Lysine, MET is Methionine, PHE is Phenylalanine, PRO is Proline, SER is Serine, THR is Threonine, TRP is Tryptophan, TYR is Tyrosine, and VAL is Valine.
Claim 84
Dependent Claim
94 words
A constructed, recombinant DNA sequence that comprises the coding sequence for the active light chain of human protein C, said active light chain having the amino acid residue sequence: ##STR15## wherein ALA is Alanine, ARG is Arginine, ASN is Asparagine, ASP is Aspartic Acid, CYS is Cysteine, GLN is Glutamine, GLU is Glutamic Acid, GLY is Glycine, HIS is Histidine, ILE is Isoleucine, LEU is Leucine, LYS is Lysine, MET is Methionine, PHE is Phenylalanine, PRO is Proline, SER is Serine, THR is Threonine, TRP is Tryptophan, TYR is Tyrosine, and VAL is Valine.
Claim 85
Dependent Claim
26 words
The DNA sequence of claim 81 wherein the coding strand is: ##STR16## wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytidyl, and T is thymidyl.
References Cited (Backward Citations)
US4438032A
Cited
US4382028A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-10-04 | 1992-04-04 | 1992-10-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-10-04 | 1996-04-04 | 1996-10-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-10-04 | 2000-04-04 | 2000-10-04 | $7700.00 | Window Closed / Lapsed |